CorrespondenceStereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer – Authors' reply
References (5)
- et al.
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Lancet Oncol
(2021) - et al.
Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT
HPB (Oxford)
(2017)
There are more references available in the full text version of this article.
Cited by (0)
© 2021 Elsevier Ltd. All rights reserved.